Cargando…

Prospects for Anti-Biofilm Pharmaceuticals

This commentary highlights several avenues currently being pursued in research labs to the development of new anti-biofilm pharmaceuticals. There is a real need for alternative therapeutic modalities for treating the persistent infections that sometimes form on implanted medical devices or compromis...

Descripción completa

Detalles Bibliográficos
Autor principal: Stewart, Philip S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588180/
https://www.ncbi.nlm.nih.gov/pubmed/26343685
http://dx.doi.org/10.3390/ph8030504
_version_ 1782392580767481856
author Stewart, Philip S.
author_facet Stewart, Philip S.
author_sort Stewart, Philip S.
collection PubMed
description This commentary highlights several avenues currently being pursued in research labs to the development of new anti-biofilm pharmaceuticals. There is a real need for alternative therapeutic modalities for treating the persistent infections that sometimes form on implanted medical devices or compromised niches within the body. Strategies being researched include discovering new antimicrobial agents that kill microorganisms in biofilms more effectively than do existing antibiotics, designing drugs that block microbial adhesion or interfere with intercellular communication, developing chemistries to disperse biofilms, and combining agents with different mechanisms of action. Though the need is great, the pathway to commercialization of new drugs is steep. One possible streamlined approach to navigating the regulatory approval process is to repurpose old drugs, a strategy that a few groups have shown can yield agents with anti-biofilm properties.
format Online
Article
Text
id pubmed-4588180
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-45881802015-10-08 Prospects for Anti-Biofilm Pharmaceuticals Stewart, Philip S. Pharmaceuticals (Basel) Commentary This commentary highlights several avenues currently being pursued in research labs to the development of new anti-biofilm pharmaceuticals. There is a real need for alternative therapeutic modalities for treating the persistent infections that sometimes form on implanted medical devices or compromised niches within the body. Strategies being researched include discovering new antimicrobial agents that kill microorganisms in biofilms more effectively than do existing antibiotics, designing drugs that block microbial adhesion or interfere with intercellular communication, developing chemistries to disperse biofilms, and combining agents with different mechanisms of action. Though the need is great, the pathway to commercialization of new drugs is steep. One possible streamlined approach to navigating the regulatory approval process is to repurpose old drugs, a strategy that a few groups have shown can yield agents with anti-biofilm properties. MDPI 2015-08-27 /pmc/articles/PMC4588180/ /pubmed/26343685 http://dx.doi.org/10.3390/ph8030504 Text en © 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Commentary
Stewart, Philip S.
Prospects for Anti-Biofilm Pharmaceuticals
title Prospects for Anti-Biofilm Pharmaceuticals
title_full Prospects for Anti-Biofilm Pharmaceuticals
title_fullStr Prospects for Anti-Biofilm Pharmaceuticals
title_full_unstemmed Prospects for Anti-Biofilm Pharmaceuticals
title_short Prospects for Anti-Biofilm Pharmaceuticals
title_sort prospects for anti-biofilm pharmaceuticals
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588180/
https://www.ncbi.nlm.nih.gov/pubmed/26343685
http://dx.doi.org/10.3390/ph8030504
work_keys_str_mv AT stewartphilips prospectsforantibiofilmpharmaceuticals